Диссертация (1154359), страница 41
Текст из файла (страница 41)
Simpson, P.Mendys // J. Clin. Lipidol. – 2012. – Vol. 4 (6). – P. 462-471.513.T.E.,Sangkuhl K., Stein C.M., Hulot J.S., Mega J.L., Roden D.M., KleinSabatineM.S.,JohnsonJ.A.,ShuldinerA.R.ClinicalPharmacogenetics Implementation Consortium. Clinical PharmacogeneticsImplementation Consortium guidelines for CYP2C19 genotype andclopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep.
№94(3). - Р.317-340.514.Sorenson, C. How can the impact of health technology assessmentbe enhanced? / C. Sorenson. - Copenhagen, WHO Regional Office for Eu-261rope,2008.(ObservatoryStudiesSeriesNo.11)(http://www.euro.who.int/document/e91271.pdf, accessed 7 April 2008).515.Sorenson, C. Ensuring value for money in health care. The role ofhealth technology assessment in the European Union European Observatory on health systems and policies / C. Sorenson, M. Drummond, P. Kanavos.
- Observatory Studies Series No 11. WHO, 2008, on behalf of theEuropean Observatory on Health Systems and Policies.Copenhagen, Denmark. ISBN 9789289071833.516.Sorenson, C. Use of comparative effectiveness research in drug cov-erage and pricing decisions: a six-country comparison / C. Sorenson // Issue Brief (Commonw Fund) 2010. – Vol. 91. – P. 1-14.517.Standards of medical care in diabetes. Diabetes Care. 2014.-№1(37).Р. 14-80.518.StegP.G., James S.K., Atar D., et al. ESC Guidelines for the man-agement of acute myocardial infarction in patients presenting with STsegment European Heart Journal.
2012.-№33(20). Р. 2569—2619.519.Suh, D.C. Clinical and economic impact of adverse drug reactions inhospitalized patients / D.C. Suh, B.S. Woodall, S.K.Shin // AnnPharmacother. – 2000. – Vol. 34(12). – P. 1373-1379.520.Systematic review and individual patient data meta-analysis of diag-nosis of heart failure, with modelling of implications of different diagnostic strategies in primary care / J.
Mant, J. Doust, A. Roalfe [et al.] // HealthTechnol Assess. – 2009. – Vol. 13 (32). – P. l-207.521.Systems analysis of adverse drug events / L. Leape, D.W. Bates, D.J.Cullen [et al.] // JAMA. – 1995. – Vol. 274. – P. 35-43.262522.Takami, S. Influence of the endothelial nitrit oxide synthase gene onconventional and ambulatory blood pressure: sib- pair analisis and haplotype study. Journal Hypertension. – 2005.
– Vol. 23. (4). – P. 759–765.523.The Cochrane Library [quarterly CD-ROM and database online]. –Oxford:UpdateSoftware,1999.ElectronicLinks:http://www.thecochranelibrary.com/view/0/index.html524.The consistency of adherence to antiretroviral therapy predicts bio-logic outcomes for human immunodeficiency virus infected persons inclinical trials / S. Mannheimer, G.
Friedland, J. Matts [et al.] // Clin. Infect. Dis. – 2002. – Vol. 34. – P. 1115-1121.525.The costs of adverse drug events in hospitalized patients / D.W.Bates, N. Spell, D.J. Cullen [et al.] // JAMA. – 1997. – Vol. 277. – P. 307311.526.The Institute for Healthcare Improvement, The Quest for Error-ProofMedicine, Drug Benefit. – 1997. – Vol. 9(6). – P. 18-29.527.Tomlin, M. Pharmacology & Pharmacokinetic a Basic Reader/M.Tomlin// New York: Springer. - 2010.
- P. 1-41.528. Tonk EC. Assessment of pharmacogenetic tests: presenting measures ofclinical validity and potential population impact in association studies / ECTonk, D Gurwitz, AH Maitland-van der Zee, AC Janssens // Pharmacogenomics J. - 2016. -doi: 10.1038/tpj.2016.34.529. US Food and Drug Administration. Table of Pharmacogenomic BiomarkersinDrugLabels.Availableat:http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. Accessed by 11.11.2014.530.Vanhove, G.F.
Patient compliance and drug failure in protease inhib-itor monotherapy / G.F. Vanhove // JAMA. – 1996. – Vol. 276(24). – P.1955–1956.263531.Vestbo J. Natural experiments and large databases in respiratory and cardiovascular disease / J Vestbo // Eur Respir Rev. – 2016.
- №25(140). – P.130-134.532.Walley, T. Health technology assessment in England: assessment andappraisal / T. Walley // The Medical Journal of Australia. – 2007. – Vol.187(5). – P. 283 – 285.533.Weintraub, W.S.Cardiovascular Health Care Economics / W.S.Weintraub // Humana Press. – 2003. – P. 119-121.534.Werlemann, B.C. Compliance problems in therapy resistant / B.C.Werlemann, E. Offers, Kolloch R.Herz // Hypertension. – 2004. – N 3. - P.271-275.535.Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G,Zhao C, et al.
Head-to-head comparison of subcutaneous abatacept versusadalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013. - №65. – Р.28–38.536.Yoon Suk, J., et al., Efficacy and safety of infliximab's biosimilar(REMSIMA) for IBD// ECCO.- 2015.P. 540..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
